Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.43 |
| ▸ | HTR1D | P28221 | 3/20 | 0.41 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945353 | 0.86 | S1PR5 (0.43) | ENPP2SCN1ASCN8AKDM4EALDH1A1 | |
| SCHEMBL4246391 | 0.86 | SCN1A (0.42) | ENPP2HTR1DSCN1ASCN8APOLB | |
| SCHEMBL8091662 | 0.85 | HRH1 (0.47) | SCN1ASCN8AHRH2ALDH1A1CCR3 | |
| SCHEMBL5526683 | 0.85 | SCN1A (0.50) | SCN1ASCN8AKDM4E | |
| SCHEMBL8104062 | 0.83 | ACHE (0.48) | ENPP2HTR1DSCN1ASCN8ACCR3 | |
| SCHEMBL8085163 | 0.81 | SCN1A (0.47) | SCN1ASCN8A | |
| SCHEMBL8100160 | 0.81 | HTR1A (0.45) | HTR1DSCN1ASCN8APOLBHTR1B | |
| SCHEMBL13945444 | 0.81 | S1PR5 (0.39) | ALDH1A1POLB | |
| SCHEMBL8097670 | 0.81 | CCR3 (0.43) | ENPP2HTR1DPOLBHTR1BCCR3 | |
| SCHEMBL8095861 | 0.81 | KCNH2 (0.41) | HTR1DSCN1ASCN8AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | ENPP2 496/4885HTR1D 483/4885SCN1A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.